Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Exclusion Criteria

• •Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic,hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness
• •Active hepatitis, hepatic insufficiency
• •Acute renal failure (de novo or superimposed to preexisting chronic renal impairment), nephrotic syndrome
• •History of or current hematuria of urologic origin that limits the subject's participation in the study
• •Subjects requiring dialysis during the study.
• •Any significant change in chronic treatment medication within 14 days before inclusion.
• •Concomitant treatment with or use of drugs or herbal agents known to be at least moderate inhibitors or inducers CYP3A4, sensitive or narrow therapeutic index substrate of CYP3A4.
• •Concomitant treatment with gastric pH modifying agents (proton pump inhibitors and H2-blockers) is not allowed 7 days prior to and 6 hours after study drug treatment
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.